CASC3 and acute lymphoblastic leukemia: To test whether this upregulation might be a prognostic marker for clinical BTZ resistance, MARCKs expression was examined in 44 primary ALL patient samples obtained from the clinical COG trial AALL07P1 using combination chemotherapy including BTZ.